Publish with Us Search
Publish with Us

Targeted Cancer Therapy Connect

ISSN: 3105-3629
Volumes

SCIFINITI ALERT!

Subscribe for research updates and exclusive content straight to your inbox

Volume 1

Articles

All Articles
Editorial

Published: 16 Jan 2026

Preface

Volume 1

It is my honor as Editor-in-Chief to present the first volume of Targeted Cancer Therapy Connect, a new peer-reviewed journal dedicated to the rapidly advancing field of targeted cancer therapeutics. The aim of this first volume and of subsequent publications is to deepen our understanding of the molecular and cellular drivers of cancer and to highlight strategies that selectively target these molecules or pathways to improve therapeutic efficacy and patient..

Journal: Targeted Cancer Therapy Connect
Review Article

Published: 17 Jun 2025

The Intratumor Microbiome: An Untapped Avenue for Translational Applications in Cancer Immunotherapeutics

Volume 1

Journal: Targeted Cancer Therapy Connect
Mini-Review

Published: 23 May 2025

Fatty Allies: How Short-Chain Fatty Acids Turn the Tumor Microenvironment Against Cancer

Volume 1

Journal: Targeted Cancer Therapy Connect
Research Article

Published: 15 Apr 2025

Association of Expression of Immune Checkpoints in Tumor-Infiltrating CD4+ T Lymphocytes with Disease-Free Survival in Colorectal Cancer Patients

Volume 1

Journal: Targeted Cancer Therapy Connect
Research Article

Published: 21 Mar 2025

Characteristics of Tumor Infiltrating Lymphocytes in Patients with Benign and Malignant Sinonasal Neoplasms

Volume 1

Introduction. Tumor infiltrating lymphocytes are a major component of sinonasal neoplasms, actively populating tumor tissue, yet their role remains poorly understood. The aim is to characterize subsets and functional profiles of tumor infiltrating lymphocytes in patients with benign and malignant sinonasal tumors. Materials and methods. Tumor infiltrating lymphocytes were isolated from the biopsy material of 58 patients: 18 with sinonasal malignancies, 23 with inverted papilloma and 17 with polypous rhinosinusitis..

Journal: Targeted Cancer Therapy Connect
Review Article

Published: 19 Mar 2025

Soluble Biomarkers as Predictors of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)-Insights from the Tumor Microenvironment Perspective

Volume 1

Lung cancer is the major cause of mortality worldwide with non-small cell lung cancer (NSCLC) contributing to 85% of the cases. FDA-approved immune checkpoint inhibitors (ICI), anti-PD-1, and anti-PD-L1 are widely used as a standard treatment. However, the response rate is limited and is observed in only 20–40% of the patients. Therefore, predictive and prognostic biomarkers are needed to help differentiate responders from non-responders, enabling a better understanding of disease..

Journal: Targeted Cancer Therapy Connect
Mini-Review

Published: 11 Feb 2025

CRISPR-Cas9 is Revolutionizing AML Treatment as a Novel Therapy

Volume 1

This review explores the progression of CRISPR-Cas9 genome editing technology in gene therapy for acute myeloid leukemia. Acute Myeloid Leukemia, a serious blood cancer, presents formidable treatment obstacles and a dismal prognosis. Effective treatments for acute myeloid leukemia rely on a clear understanding of its intricate genetic mechanisms, and CRISPR-Cas9 technology offers precision and adaptability for targeting the disease’s oncogenic drivers. The dual intron-targeting method of CRISPR-Cas9 is showcased in..

Journal: Targeted Cancer Therapy Connect
Review Article

Published: 08 Jan 2025

Chronic Myelomonocytic Leukemia Relapse After Transplant

Volume 1

Relapse of Chronic Myelomonocytic Leukemia after allogeneic hematopoietic stem cell transplantation remains a significant challenge, with relapse rates reaching up to 50%, contributing to poor survival outcomes. This paper explores the factors influencing relapse, including disease biology and persistence of residual disease. Current, post- transplant strategies, such as maintenance therapies and immunomodulatory treatments, are discussed for their potential to reduce the likelihood of relapse. It also highlights emerging therapies, such..

Journal: Targeted Cancer Therapy Connect
Review Article

Published: 21 Oct 2024

Neoantigen-Based Cancer Vaccines: Current Innovations, Challenges and Future Directions in Personalized Immunotherapy

Volume 1

Journal: Targeted Cancer Therapy Connect
Mini-Review

Available Online: 23 Dec 2025

Covalent BH3-Mimetics and PROTACs Targeting BCL2 Family for Precision Apoptosis Induction

Volume 1

The BCL2 family of proteins serves as a central regulator of mitochondrial outer membrane permeabilization (MOMP) and intrinsic apoptosis, with anti-apoptotic members such as BCL2, BCL-XL, and MCL1 frequently overexpressed in cancers to evade programmed cell death. Traditional BH3 mimetics, like venetoclax and navitoclax, have revolutionized treatment for hematologic malignancies by competitively inhibiting these pro-survival proteins, yet they face challenges including acquired resistance, on-target toxicities and limited efficacy in solid..

Journal: Targeted Cancer Therapy Connect
Share
Help